Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Position Boosted by BML Capital Management LLC

BML Capital Management LLC grew its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 9.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,250,000 shares of the biotechnology company's stock after purchasing an additional 1,261,866 shares during the period. Aclaris Therapeutics makes up about 9.6% of BML Capital Management LLC's investment portfolio, making the stock its 4th largest position. BML Capital Management LLC owned approximately 19.97% of Aclaris Therapeutics worth $16,388,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ACRS. Stonepine Capital Management LLC bought a new position in shares of Aclaris Therapeutics in the second quarter worth $2,120,000. Trium Capital LLP purchased a new stake in Aclaris Therapeutics during the 2nd quarter worth approximately $2,081,000. Russell Investments Group Ltd. lifted its stake in shares of Aclaris Therapeutics by 5,265.1% in the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company's stock worth $78,000 after acquiring an additional 61,602 shares during the period. BNP Paribas Financial Markets increased its position in Aclaris Therapeutics by 10.9% during the first quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company's stock worth $299,000 after purchasing an additional 23,747 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Aclaris Therapeutics by 1.9% in the 2nd quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company's stock worth $3,671,000 after acquiring an additional 63,358 shares during the period. 98.34% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. StockNews.com cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, November 7th. HC Wainwright restated a "neutral" rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th. One research analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $9.00.

Aclaris Therapeutics Trading Down 2.7 %

Aclaris Therapeutics stock traded down $0.07 during midday trading on Tuesday, reaching $2.56. The stock had a trading volume of 628,495 shares, compared to its average volume of 999,829. Aclaris Therapeutics, Inc. has a 12 month low of $0.59 and a 12 month high of $2.68. The company has a fifty day moving average price of $1.40 and a two-hundred day moving average price of $1.27. The company has a market capitalization of $182.86 million, a P/E ratio of -4.69 and a beta of 0.10.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The business had revenue of $4.35 million for the quarter, compared to analysts' expectations of $8.31 million. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. On average, equities research analysts predict that Aclaris Therapeutics, Inc. will post -0.67 earnings per share for the current fiscal year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.